Universitat de Barcelona

Universitat de Barcelona appears in the evidence as a university-based clinical and research institution connected with the management of hepatitis C in kidney disease. The clearest institutional identification places its Department of Nephrology and Renal Transplantation within Hospital Clinic, Universitat de Barcelona, and IDIBAPS in Barcelona, Spain. In that setting, specialist work examines patients receiving long-term dialysis and addresses the consequences of HCV infection for renal and transplant medicine.

Institutional Setting and Clinical Scope

Universitat de Barcelona is presented not as an isolated administrative body but as part of a nephrology and renal-transplantation environment in which HCV is studied alongside end-stage renal disease, dialysis, and transplantation. The associated clinical work treats HCV-related liver disease as a major problem for patients with chronic kidney disease, even when the infection is clinically quiet. In long-term dialysis populations, HCV-related liver disease is mostly asymptomatic; fatigue, asthenia, and cognitive impairment are difficult to interpret because they also occur commonly in dialysis patients without HCV. The institutional setting therefore requires laboratory assessment and structured staging rather than reliance on symptoms alone.

The clinical questions attached to this setting extend beyond the liver. HCV infection can produce extrahepatic disease, including cryoglobulinemia-associated vasculitis and immune-complex glomerular disease. Mixed cryoglobulinemia is characterized by findings such as arthralgias, purpura, neuropathy, hypocomplementemia, and kidney disease, while renal involvement may appear as proteinuria, hematuria, reduced estimated glomerular filtration rate, nephritic syndrome, or nephrotic syndrome. This breadth explains why nephrology and renal transplantation are central to the institution's documented role: HCV is treated as a systemic condition whose consequences may reach the native kidney, the dialysis patient, and the renal allograft.

Diagnostic and Assessment Framework

The evidence associated with Universitat de Barcelona emphasizes the separation of antibody status from active infection. Diagnosis begins with anti-HCV antibodies detected by third-generation enzyme-linked immunosorbent assay. Antibodies alone cannot distinguish resolved infection from chronic infection; active infection is established by detecting HCV RNA in serum with sensitive molecular assays, whose threshold is approximately 15 IU/ml. Chronic infection requires both anti-HCV positivity and HCV RNA positivity, with active chronic infection described as persistence for more than six months.

Once active infection is established, evaluation must cover both hepatic and extrahepatic effects. Liver injury is assessed by its stage and grade through liver biopsy or noninvasive methods. Biochemical scores such as Fibrotest, Fibrometre, Hepascore, Forns index, and Fib-4, together with elastometry by FibroScan, can reduce the need for approximately half of liver biopsies and permit yearly follow-up of fibrosis in untreated patients. The evidence nevertheless preserves an important distinction between useful noninvasive surveillance and definitive assessment: in HCV-infected kidney-transplant candidates, percutaneous liver biopsy remains the recommended and most reliable method for determining the extent of fibrosis.

This diagnostic discipline is particularly important because advanced liver injury may remain hidden. Up to 25% of patients with active HCV infection have advanced fibrosis on liver biopsy, often with well-compensated disease that would not otherwise arouse suspicion. Accordingly, transplant candidates require systematic screening. In low-prevalence regions, initial testing uses enzyme immunoassay, followed by nucleic-acid testing when antibodies are detected; in high-prevalence settings, nucleic-acid testing should be the first-line test because a negative antibody assay cannot reliably exclude infection.

Dialysis Research and Patient Experience

The institutional evidence places HCV within the everyday complexity of long-term dialysis. In a large United States cohort of 13,664 dialysis patients, anti-HCV seropositivity was independently associated with serum alkaline-phosphatase activity after adjustment for several covariates, including surrogates of malnutrition-inflammatory complex syndrome. HCV-infected patients also had higher intact parathyroid hormone levels than comparison patients, an observation linked to hepatic osteodystrophy. Yet dialysis patients commonly have arterial hypertension, gastrointestinal bleeding, anemia, vascular-access failure, and other comorbidities, so biochemical abnormalities may be overlooked in routine care. Cirrhosis, by contrast, was described as relatively infrequent in dialysis patients in the Western world, occurring in approximately 1.5% to 2% according to international registries.

The evidence also connects HCV with vascular risk, although the broader mortality literature is not uniform. In a prospective study of 94 dialysis patients, 17 of whom were HCV positive, HCV viremia and mean blood pressure were independently associated with high aortic stiffness, defined as a carotid-femoral pulse-wave velocity of at least 10.0 m/s. Event-free survival curves for cerebrovascular and cardiovascular events differed significantly according to HCV RNA status, leading the investigators to suggest an atherogenic role through worsening metabolic syndrome and dyslipidemia. A meta-analysis of observational studies, however, found an unadjusted cardiovascular-mortality risk estimate of 0.95 with a 95% confidence interval of 0.76 to 1.18, not statistically significant. The institutional evidence thus preserves both the mechanistic signal and the uncertainty of population-level mortality estimates.

Quality of life forms another part of the documented clinical picture. Among 165 regular dialysis patients, 83 were anti-HCV positive. Anti-HCV-positive status was independently associated with a lower mental component summary score on the 36-item SF-36, with a coefficient of -3.423 and a p value of 0.016, while no association was found with the physical component summary score. Depression may mediate part of this relationship: it can follow the diagnosis and fears about long-term health, or arise alongside fatigue and cognitive impairment, while hemodialysis itself increases the prevalence of depression. This makes HCV management relevant not only to virologic or histologic markers but also to mental well-being and the lived burden of treatment.

Transplant Evaluation and Waiting-List Governance

Universitat de Barcelona's documented nephrology context also intersects with the high-stakes process of kidney-transplant assessment. All candidates should be screened for anti-HCV antibody and, where appropriate, active viremia through nucleic-acid testing. Patients with active HCV infection require staging of liver disease, and established or decompensated cirrhosis should prompt referral to a liver-transplant team for consideration of combined liver-kidney transplantation rather than kidney transplantation alone.

The waiting list is treated as a period of active surveillance rather than administrative suspension. In areas where deceased-donor waiting times approach five to seven years, patients with HCV require repeated assessment to ensure that progressive liver disease has not made kidney-alone transplantation unsuitable. Patients who are newly found to have positive nucleic-acid testing should be placed on hold and referred to a hepatologist for evaluation and possible treatment. Those who have achieved a sustained virologic response should undergo at least annual nucleic-acid testing to confirm that the response persists; relapse similarly warrants hold status and consideration of retreatment. Patients who remain viremic require annual evaluation for progression of liver disease.

The evidence shows why this surveillance matters. Among 13 patients who underwent repeat liver biopsy while remaining on the waiting list, 8, or 62%, showed worsening liver histology. By comparison, only 7 of 31, or 23%, of follow-up biopsies obtained after transplantation showed interval worsening. These figures do not erase the need for monitoring after transplantation, but they place the waiting period itself under clinical scrutiny: prolonged time before transplantation can expose an HCV-infected candidate to continuing hepatic injury.

Treatment, Transplantation, and Renal Allograft Consequences

The clinical literature associated with this institutional setting treats antiviral therapy as a decision shaped by timing and toxicity. Treatment can be recommended at any stage of HCV infection; in acute infection, persistent HCV RNA after an average of 12 weeks indicates a 24-week course of pegylated interferon, with ribavirin added for patients coinfected with HIV. Detectable RNA at week four or week twelve may require extension to 48 weeks. In chronic infection, treatment is considered according to clinical impact, including fatigue, necroinflammation, fibrosis, or symptomatic extrahepatic disease such as cryoglobulinemia-associated vasculitis.

The pretransplant period is especially important because interferon after transplantation is associated with an increased risk of renal-allograft rejection. The evidence therefore favors concentrating efforts to eradicate HCV before transplantation whenever feasible. A sustained virologic response before transplantation appears, in most patients, not to relapse after immunosuppression is introduced, although the evidence is limited regarding whether pretransplant clearance slows later liver-injury progression. Pretransplant clearance may also reduce the risk of post-transplant diabetes and immune-complex glomerular disease in the allograft, but this possibility is described as supported mainly by anecdotal evidence rather than definitive trials.

Therapy itself carries a substantial burden. Interferon-associated toxicity can reduce quality of life, prompt dose reduction in 35% to 42% of patients, and lead to discontinuation in approximately 30%. Flu-like symptoms include fever, fatigue, headache, myalgia, and arthralgia; hematologic effects include anemia and neutropenia; and neuropsychiatric effects include depression and anxiety. These risks place the institution's clinical work at the intersection of viral eradication, transplant timing, patient endurance, and the preservation of mental and physical quality of life.

HCV also remains relevant after a renal transplant has been performed. It is identified as a major risk factor for renal-allograft loss and an independent predictor of graft outcome, although part of the apparent effect may reflect the high immunologic risk of the HCV-infected population, including retransplantation, prolonged renal disease, and stronger cellular and humoral immune responses. HCV infection has been associated with glomerulitis and transplant glomerulopathy, conditions linked to anti-HLA antibodies and antibody-mediated rejection. It is also associated with thrombotic microangiopathy in renal allografts in the presence of pretransplant anticardiolipin antibodies, although that complication is seldom encountered.

HCV-infected renal and liver allograft recipients are prone to immune-complex-mediated glomerulonephritis. De novo membranoproliferative glomerulonephritis has been reported in HCV-infected renal-allograft recipients, later linked to type II mixed cryoglobulinemia with IgM-kappa monoclonal components. In these recipients, cryocrit levels are often below 5%, which can make cryoglobulin detection and characterization difficult, while HCV RNA may be much more concentrated in the cryocrit than in serum, supporting a pathogenic role for the virus. Clinical manifestations include hypertension, microhematuria, proteinuria, renal dysfunction, and sometimes nephrotic syndrome. Biopsy may show mesangial proliferation, double contours, and parietal IgM and C3 deposits; electron microscopy can be needed to distinguish membranoproliferative glomerulonephritis from transplant glomerulopathy, and the two lesions can coexist. HCV-associated membranous glomerulonephritis has also been described in renal allografts, usually with nephrotic syndrome, although its mechanism remains unclear because cryoglobulins, immune complexes, and complement activation are often absent.

Infection Control and Institutional Significance

The broader institutional context includes prevention of HCV transmission in dialysis units. A KDIGO review of 20 molecular-virology studies found no conclusively established transmission route in any study, but all suggested failures in infection-control procedures as the probable cause of new cases. In 18 of the 20 studies, some or all newly infected patients did not share a dialysis machine with the presumed source patient, indicating that the internal machine circuit played at most a small role in nosocomial transmission. On that basis, the workgroup did not recommend dedicated dialysis machines for HCV-infected patients.

The same evidence does not support patient isolation as a substitute for rigorous infection control. Two large prospective observational studies, including the Dialysis Outcomes and Practice Patterns Study and an Italian study, found after multivariable adjustment that isolation did not protect against HCV transmission. The recommendation was therefore against isolating HCV-infected patients as an alternative to strict infection-control procedures for bloodborne pathogens. This conclusion gives the university-linked clinical perspective a practical institutional edge: prevention depends less on segregating a diagnosis than on consistently controlling the procedures through which blood exposure can occur.

Universitat de Barcelona's significance in the supplied evidence lies in this integration of laboratory definition, organ assessment, dialysis medicine, transplant eligibility, patient experience, treatment toxicity, and allograft pathology. Its named setting connects HCV to a chain of decisions in which an antibody result must be separated from active viremia, silent fibrosis must be found before transplantation, waiting-list status must be revisited over years, and a cleared infection must still be understood in relation to immunosuppression and graft survival. The institution thus represents a clinical-academic model in which HCV is neither merely a liver diagnosis nor merely a laboratory result, but a condition reorganizing the management of the entire renal-transplant pathway.